Friday, July 31, 2020

Bill Belichick - Cam Newton will have to win Patriots' starting QB job - ESPN

Bucks or the field: Who wins the Eastern Conference? | The Jump - ESPN

Job-hunting: 'I apply everywhere - few firms reply'

The pandemic has created a desperate hunt for jobs in an increasingly competitive market.

from BBC News - Business https://ift.tt/2PaXWp3

Jet2 to refund customers returning early from Spain

The airline says it will refund cancelled return flights from Spain and unused holiday dates.

from BBC News - Business https://ift.tt/3feR6cJ

BA staff and plane fanatics hunt for 747 souvenirs

The retirement of British Airways' fleet of 747s has triggered a bout of nostalgia from its fans.

from BBC News - Business https://ift.tt/30hHyJN

Red Sox' Michael Chavis paying attention to outbreaks while keeping safety in mind

When you start thinking about mistakes you start making mistakes,” Godley said. The biggest thing is staying positive and trying to attack the zone and attack the hitters. A lot of guys try to shy away from these guys simply because they are who they are.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/2CY62in

Alex Verdugo 'a great candidate' for MLB's 'Let the Kids Play' campaign, Michael Chavis says

But it’s also clear he’s having fun. He hustles and shows his fiery personality when he plays. You can tell he has fun playing the game,” teammate Michael Chavis said.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/39N5ffO

It took awhile, but Christian Vazquez has caught on for Red Sox

None has been in the Red Sox organization as long as Christian Vazquez, a player who has developed in 12 years since being drafted in 2008 into an unlikely franchise cornerstone. In a 60-game season, it feels as if Vazquez has already saved the Red Sox from oblivion. He was a game-changing offensive force in a two-game sweep of the Mets in CitiField, going 4 for 8 with three homers while driving in six and helping to navigate the pitching staff through steady waves of high-leverage situations.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/39K2WdD

WATCH: Yankees great CC Sabathia throws 1st pitch to Gerrit Cole before home opener vs. Red Sox

No cutter? Yankees great CC Sabathia threw the first pitch before the 2020 home opener at Yankee Stadium on Friday. Sabathia threw it from the rubber and bounced it, low and away, to ace Gerrit Cole.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/2Xgofyk

Why a new generation of Thais are protesting against the government

A new political divide in Thailand has emerged between the country's youth and its older generation.

from BBC News - World https://ift.tt/3fi6QLZ

US election 2020: The war hero who could be Biden's running mate

Senator Tammy Duckworth is an Iraq war veteran and the first Thai-American woman elected to Congress.

from BBC News - World https://ift.tt/339acyu

India coronavirus: Gold rush as pandemic roils country's economy

As Covid-19 worsens the economic slump, Indians are returning to a trusted asset: gold.

from BBC News - World https://ift.tt/30evlp4

Belarus: The mother challenging an authoritarian president

Political novice Svetlana Tikhanovskaya rallies protesters in a battle with Alexander Lukashenko.

from BBC News - World https://ift.tt/339JHZM

Fauci clashes with Rep. Jim Jordan at House coronavirus hearing - Business Insider - Business Insider

Supreme Court allows continued construction of Trump's border wall - CNN

'A classic do no harm strategy': Biden's campaign enters key stretch - NBC News

Trump campaign temporarily pauses ad spending to review its messaging - The Washington Post

Trump campaign temporarily pauses ad spending to review its messaging  The Washington Post

from Top stories - Google News https://ift.tt/3ghinwp

As Trump suggests delaying election, White House condemns Hong Kong for postponing its own vote - ABC News

In Pictures: Hajj in the shadow of coronavirus - Aljazeera.com

Google is about to fix the most annoying thing about Chromebooks - Android Central

SkinStore Sale: Get 25% Off Select Items

Shop the newest beauty products on discount.

from News https://ift.tt/3ggZU36

'Scandal' Star Katie Lowes Expecting Baby No. 2 With Husband Adam Shapiro

The actress and her husband, Adam Shapiro, announced the exciting news via Instagram on Friday.

from News https://ift.tt/3hZQbyB

Reebok Sale: 50% Off Outlet at Reebok

Shop deep discounts on Reebok favorites.

from News https://ift.tt/2BKPNEu

Thursday, July 30, 2020

Desi Perkins Launches New Fashion Brand DEZI -- See Her First Sunglass Collection!

The brand-new collection, dropping Friday, features six styles and 26 colorways.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/2Pcu1MY

Kerry Washington on Bringing Marginalized Stories to the Forefront (Exclusive)

The actress also talks about her latest project, the documentary 'The Fight.'

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/3f9U2ao

Joey Logano on racing at his 'home track' and NASCAR during the pandemic

NBC Sports Boston's Danielle Trotta chats with NASCAR star and New England native Joey Logano about the upcoming Cup Series race at New Hampshire Motor Speedway.



from Nascar Racing News, Photos, Stats, Scores, Schedule & Videos https://ift.tt/39GiW0h

LEADING OFF: Yelich, Springer slumping, Blue Jays wandering

Two-time defending NL batting champion Christian Yelich has a long way to go if he wants a three-peat. Yelich also has struck out 12 times going into the series opener at home against Jack Flaherty and the Cardinals. Former World Series MVP George Springer (.048), two-time batting champ Jose Altuve (.174) and former All-Star Game MVP Alex Bregman (.174) will look to break loose when the Astros visit the Angels.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/317XHAq

Covid-19: Why Hong Kong's 'third wave' is a warning

Until recently, the city was seen as a poster child in its handling of the pandemic. What went wrong?

from BBC News - World https://ift.tt/30bOnfN

What exactly is a 'Karen' and where did the meme come from?

To many the Karen meme - and its male equivalent Ken - sums up a specific type of white privilege.

from BBC News - World https://ift.tt/3gioFf9

The 'real' threat to Russia’s former doping mastermind

The ex-mastermind of Russian sports doping, Grigory Rodchenkov, now only appears in disguise. Matt Majendie explains why.

from BBC News - World https://ift.tt/314ezIn

Bollywood's 'warts and all' biopic on 'human computer'

Bollywood actress Vidya Balan plays Shakuntala Devi who dazzled the world with her skill with numbers.

from BBC News - World https://ift.tt/3ggIC6b

The middle-css Pakistani students fighting for a homeland dream

Shahdad Mumtaz died for his beliefs. Could a missing student end up waging war on the Pakistani state?

from BBC News - World https://ift.tt/312Wk6b

Coronavirus: Brits, Balearics and battered businesses

Ibiza's nightclub scene has been hit hard by coronavirus, leaving people in need of support.

from BBC News - World https://ift.tt/3fm4ko8

Dam Fire Erupts In Angeles National Forest Area North Of Azusa - CBS Los Angeles

Pelosi responds to Trump floating election delay by quoting from Constitution | TheHill - The Hill

Trudeau denies 'preferential treatment' in ethics scandal - BBC News

Ford's slumping sales buoyed by autonomous vehicle investment - CNN

Naya Rivera To Appear On ‘Sugar Rush’; Netflix Dedicates Episode To Late Actress Following Her Tragic Death - Deadline

LeBron James' intensity, Zion Williamson's return, Lakers-Clippers among top storylines as NBA restarts season - CBS Sports

Kylie and Kendall Jenner endorsed 'knock-off' Apple products on Instagram

They promoted AirPods clones, whose design may be in breach of Apple's intellectual property rights.

from BBC News - Technology https://ift.tt/2XelXzL

What you need to become an internet streaming star

Broadcasting on services like Twitch is becoming increasingly popular - and more professional.

from BBC News - Technology https://ift.tt/30dZEMv

Best New Clothes From Old Navy in July -- 25% Off Purchase, Including Clearance

Shop the 2400 new arrivals already on sale at Old Navy.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/39HG12q

Naya Rivera's Final TV Appearance Will Be on Netflix's 'Sugar Rush'

The late actress filmed her episode of the baking competition show in February.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/33fv72P

How Selena Gomez, Becky G and Other Latinx Celebs Are Supporting the Black Lives Matter Movement

A look at how Latin American celebrities are supporting the BLM movement and pushing the narrative forward.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/2BKEIDr

'America's Got Talent' Live Shows Kick Off Next Month -- Here Are the 44 Acts That Made It!

'AGT' season 15's live quarterfinals are around the corner, and here's a look at who will be facing off first!

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/2P8qtLF

'Black Is King,' 'Homecoming' and More: How to Watch Every Beyoncé Film Streaming Right Now

From 'Lemonade' to 'Life Is But a Dream' and everything in between.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/3jYXM1W

Wednesday, July 29, 2020

Moderna: Phase 3 Trial and Additional BARDA Funding Outweigh IP Issues, Says Top Analyst

Moderna: Phase 3 Trial and Additional BARDA Funding Outweigh IP Issues, Says Top AnalystOn Sunday, Moderna (MRNA) disclosed it had been awarded an extra $472 million from the Biomedical Advanced Research and Development Authority (BARDA) to further support the development of mRNA-1273, its experimental COVID-19 vaccine. The new award follows a $483 million grant provided by BARDA in April, which means Moderna has now received a total of $955 million in funding from the U.S. government.The award coincides with the initiation of Moderna’s Phase 3 study of mRNA-1273. The study began on Monday with the dosing of the first patients in the 30,000-participant study across 87 trial sites. If all goes according to plan, efficacy data for the study could become available as soon as Thanksgiving.After gaining nearly 385% since the turn of the year, Moderna shares experienced a rare setback last week following a ruling by the US Patent and Trademark Office (USPTO), which rejected Moderna’s claim that Arbutus Biopharma’s US patent on lipid nanoparticle (LNP) formulations should be revoked.However, Chardan analyst Geulah Livshits argues the verdict will have little impact on Moderna’s COVID-19 vaccine program. The 5-star analyst commented, “We would not anticipate IP negotiations to delay mRNA-1273 commercialization given the obviously important public health impact of a SARS-CoV-2 vaccine and the high degree of motivation among government agencies to roll out a vaccine as soon as possible. Moreover, we believe awards supporting development of mRNA-1273 and broader manufacturing scale-up reduce COGS across the platform and to us suggest Moderna's pipeline can become profitable even if royalty payments come into play in the future.”To this end, Livshits rates MRNA a Buy along with a $95 price target, which implies nearly 20% upside from current levels. (To watch Livshits’ track record, click here)When it comes to Moderna, Livshits’ colleagues hardly deviate from the Chardan playbook. MRNA's Strong Buy consensus rating is based on 13 Buy ratings and 4 Holds. The Street thinks a 17% premium will be added to MRNA shares over the next 12 months, going by the $90.67 average price target. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.




from Yahoo Finance https://ift.tt/339dge2

Inovio's Drug For Rare Respiratory Tract Disorder Granted Orphan Designation

Inovio's Drug For Rare Respiratory Tract Disorder Granted Orphan DesignationInovio Pharmaceuticals Inc (NASDAQ: INO) shares were volatile Wednesday after the company announced Orphan Drug Designation for one of its pipeline drugs.What Happened: The Plymouth, Pennsylvania-based company said the FDA granted ODD for INO-3107, a DNA medicine that's being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis, or RRP.RRP is a rare disease caused by human papillomavirus types 6 and 11 infections that causes non-cancerous tumor growths leading to life-threatening airway obstructions, the company said.Why It's Important: The ODD from the FDA qualifies INO-3107 for various development incentives, including a tax credit on expenditures incurred in clinical studies; a waiver of the new drug application fee; a research grant awarded by the FDA; and most importantly, seven years of U.S. market exclusivity upon approval for the treatment of RRP, Inovio said."Receiving FDA's orphan drug designation for INO-3107 is an important milestone in the development of Inovio's DNA medicine for this rare disease and clearly underscores the importance of addressing the unmet medical need for this debilitating condition," Ami Shah Brown, Inovio's senior vice president fo regulatory affairs, said in a statement.Inovio is developing a DNA vaccine for SARS-CoV2, the virus that causes COVID-19. The vaccine program is embroiled in litigation with its CDMO partner, as well as a shareholder lawsuit accusing the company of stock pumping.The company is scheduled to report second-quarter results Monday, Aug. 10.INO Price Action: At last check, Inovio shares were sliding 4.23% to $19.91.Related Links: The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally See more from Benzinga * Inovio Subcontractor Hits Back With Lawsuit Against Coronavirus Vaccine Developer * The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




from Yahoo Finance https://ift.tt/3gcNQj8

Alibaba Group Holding (NYSE:BABA) Has A Rock Solid Balance Sheet

Alibaba Group Holding (NYSE:BABA) Has A Rock Solid Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...




from Yahoo Finance https://ift.tt/307yEhH

Moderna: Phase 3 Trial and Additional BARDA Funding Outweigh IP Issues, Says Top Analyst

Moderna: Phase 3 Trial and Additional BARDA Funding Outweigh IP Issues, Says Top AnalystOn Sunday, Moderna (MRNA) disclosed it had been awarded an extra $472 million from the Biomedical Advanced Research and Development Authority (BARDA) to further support the development of mRNA-1273, its experimental COVID-19 vaccine. The new award follows a $483 million grant provided by BARDA in April, which means Moderna has now received a total of $955 million in funding from the U.S. government.The award coincides with the initiation of Moderna’s Phase 3 study of mRNA-1273. The study began on Monday with the dosing of the first patients in the 30,000-participant study across 87 trial sites. If all goes according to plan, efficacy data for the study could become available as soon as Thanksgiving.After gaining nearly 385% since the turn of the year, Moderna shares experienced a rare setback last week following a ruling by the US Patent and Trademark Office (USPTO), which rejected Moderna’s claim that Arbutus Biopharma’s US patent on lipid nanoparticle (LNP) formulations should be revoked.However, Chardan analyst Geulah Livshits argues the verdict will have little impact on Moderna’s COVID-19 vaccine program. The 5-star analyst commented, “We would not anticipate IP negotiations to delay mRNA-1273 commercialization given the obviously important public health impact of a SARS-CoV-2 vaccine and the high degree of motivation among government agencies to roll out a vaccine as soon as possible. Moreover, we believe awards supporting development of mRNA-1273 and broader manufacturing scale-up reduce COGS across the platform and to us suggest Moderna's pipeline can become profitable even if royalty payments come into play in the future.”To this end, Livshits rates MRNA a Buy along with a $95 price target, which implies nearly 20% upside from current levels. (To watch Livshits’ track record, click here)When it comes to Moderna, Livshits’ colleagues hardly deviate from the Chardan playbook. MRNA's Strong Buy consensus rating is based on 13 Buy ratings and 4 Holds. The Street thinks a 17% premium will be added to MRNA shares over the next 12 months, going by the $90.67 average price target. (See Moderna stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.




from Yahoo Finance https://ift.tt/339dge2

Draftkings (DKNG) Stock Might Be Expensive, Stay Cautious

Draftkings (DKNG) Stock Might Be Expensive, Stay CautiousMcLain Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The fund posted a return of -15.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned 20.5% in the same quarter. However, you should check out McLain Capital's top 5 stock picks […]




from Yahoo Finance https://ift.tt/314ut5M

ZoomInfo Technologies (ZI) Stock Might Be Expensive, Stay Cautious

ZoomInfo Technologies (ZI) Stock Might Be Expensive, Stay CautiousMcLain Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The fund posted a return of -15.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned 20.5% in the same quarter. However, you should check out McLain Capital's top 5 stock picks […]




from Yahoo Finance https://ift.tt/334RiIV

Industry Analysts Just Made A Meaningful Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Revenue Forecasts

Industry Analysts Just Made A Meaningful Upgrade To Their CRISPR Therapeutics AG (NASDAQ:CRSP) Revenue ForecastsCRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the analysts making...




from Yahoo Finance https://ift.tt/2EoHO0Q

Kodak Craziness Is Captured in One Word: Really?

Kodak Craziness Is Captured in One Word: Really?(Bloomberg Opinion) -- Kodak, the once-iconic photo company that’s been languishing for years, surprised the world this week by announcing a pivot into the pharmaceuticals business with a $765 million head start from the U.S. government. Somehow, that was enough to send the stock soaring more than 1,000% and add more than $1 billion to the company’s market value. Really? Let’s discuss. The Defense Production Act loan, announced Tuesday, is part of a Trump administration effort to bring the manufacture of drug ingredients back to U.S. shores to reduce dependence on other countries and ensure consistent supply. It's a reasonable if challenging policy goal. The loan and new business line for Eastman Kodak Co. isn't, however, anything close to a justification for its massive share-price gains — whatever day traders and Robinhood investors may say.Kodak is attempting to enter a low-margin commodity market with no particular advantage outside of the current administration's industrial policy. Unless the government money spigot keeps flowing, it's hard to imagine the company ever living up to its lofty valuation.Many of the world's pharmaceutical ingredients come from China or India. This has become a concern in recent years because of quality-control issues and the recent specter of pandemic-related shortages. However, shifting the supply chain back to the U.S. isn't the work of a few loans or a few years.Re-shoring sounds appealing, but it's challenging to successfully break into a commodity business from a standing start even with a boost from the government. And drug ingredients made in America by an inexperienced new entrant are likely to be more expensive than those available abroad in the absence of extreme and rare supply shocks. Many large generic drugmakers that also make and use drug ingredients have been facing significant pricing pressure and slashing costs for years; few are likely to consistently buy American from a new source unless the government forces them. What’s more, higher ingredient costs would potentially filter through to higher drug prices, which is not exactly a popular idea.Part of the enthusiasm may stem from the fact that Kodak reportedly aims to make drug ingredients used in the fight against Covid-19, including hydroxychloroquine, a medicine that President Donald Trump continues to tout as a possible treatment even though it has repeatedly failed to show a benefit in clinical trials. To turn that into an investment thesis for Kodak, you have to believe that the medicine will finally succeed in a well-controlled trial, or that off-label prescriptions will be common. You have to think that the company, which has been out of the drug business for decades, will be able to retrofit factories and significantly ramp up production before vaccines or more effective treatments emerge. You have to believe that the company can compete on cost giants that have been in this business for decades or that Congress will pass a mandate handing it a market.  It's unclear if anyone's buying Kodak because they truly believe in the long-term potential of this project, as opposed to just day trading. Either way, good luck. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.




from Yahoo Finance https://ift.tt/2P3QuMn

Our Take On Kroger's (NYSE:KR) CEO Salary

Our Take On Kroger's (NYSE:KR) CEO SalaryWilliam McMullen became the CEO of The Kroger Co. (NYSE:KR) in 2014, and we think it's a good time to look at the...




from Yahoo Finance https://ift.tt/2Der9wr

Alphabet Reports Q2 Earnings: Focus Is On Cloud and Streaming Services

Alphabet Reports Q2 Earnings: Focus Is On Cloud and Streaming ServicesWhen Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG) opened its Q1 earnings book last April, the numbers weren't all that stellar. It was an earnings miss. Later that day, during post-bell extended trading, its shares soared as much as 7%. Three months later, GOOGL had advanced roughly 21%.So what happened? Maybe amid COVID-19 uncertainties, investors had been expecting worse, and consensus from Wall Street might have priced in all that uncertainty. Apparently, in the eyes of the market, not bad enough was "good enough" to propel the stock upward. It's time for a fresh snapshot from the Communication Services giant. Here's what we might expect when GOOGL opens its earnings book to reveal Q2 results after Thursday's close.Alphabet's Tepid Earnings Miss and Revenue Beat GOOGL's Q1 adjusted earnings came in at $9.87 per share, which was below consensus estimate of $10.86. The company posted $41.16 billion in revenue, beating analyst expectations of $40.64 billion.The big story, if you remember, was about YouTube and the Cloud. As businesses began shutting down, the "stay at home" economy was just ramping up, GOOGL's YouTube and Cloud services provided home-based access to the outside world; just what everyone needed for work and play when people were stuck in the confines of four walls and a roof.As expected, usage surged during the "lockdown" across all Google products--search, classroom, YouTube, and Android apps, you name it. Maybe GOOGL CEO Sundar Pichai said it best when he told analysts during the Q1 conference call that search activity alone was "four times greater than during the peak of the Super Bowl." Of course, who wasn't Googling coronavirus-related stuff?Google Cloud Platform Outpaced Other Cloud Services GOOGL's cloud division posted $2.78 billion in revenue during Q1, up 52% year over year. Looking into the details, Alphabet's Google Cloud Platform infrastructure outpaced all other units in the company's cloud segment. Overall, the Q1 figure matched the one right before it (up 53% year over year in Q4), showing, if anything, some signs of steady growth. Looking at other cloud-based services, Google Classroom doubled its usage starting in early March. They ended last quarter with 100 million students and teachers. As COVID concerns continue into the fall semester, it'll be interesting to see what the Q2 figures reveal, as it's unclear whether school districts, teachers, and students are ready to trade in the virtual classroom for a real one just yet. Along with virtual learning (among other needs) came a demand for laptops. Chromebook sales saw a massive surge of 400% year over year in March. As far as virtual meetings are concerned, Google Meet may not be the "hippest" name in the culture of Zoom Video Communications (NASDAQ: ZM), but it did see an increase of up to 100 million users in Q1--another thing to maybe keep an eye on when the company reports Q2 results. Plus, the videoconferencing arena is heating up with another major titan--Microsoft Corporation (NASDAQ: MSFT) and its Teams platform.It's safe to say that Q1 cloud growth was more or less expected, given the lockdown circumstances. The same could be said for YouTube. In fact, usage for that platform saw a massive Q1 increase. But its revenue growth tells a different story, one that didn't go as smoothly as expected.YouTube Advertising Revenue Was a Downer...Somewhat YouTube's Q1 advertising got the spotlight--meaning it wasn't viewed in the best light. YouTube usage surged as subscriptions steadily grew. But advertising revenue of $4.04 billion (up 33% from the same quarter a year earlier) was considered relatively weak. CFO Ruth Porat described it as "an abrupt decline." CEO Pichai elaborated, "The first two months of the quarter were strong," but then "we experienced a significant and sudden slowdown in ad revenues" due to pandemic effects. The big hit came from brand advertising, it appears. Other YouTube ads, particularly direct response ads, maintained their momentum. Ultimately, YouTube ad growth might have been kind of a downer compared with expectations from Wall Street, but still, 33% year over year growth doesn't sound too shabby. As businesses across the globe began to reopen in Q2, YouTube ad revenue may be something to watch as "overall recovery in ad spend will depend on a return to economic activity," Pichai said. Will business reopenings in Q2 reflect enough confidence among bigger brands to restart their ad campaigns? Nobody knows for sure. But when they do, we can only imagine how that might potentially boost revenue for GOOGL if and when big brand ad spending ramps up.Queuing Ahead to Q2 The Communication Services sector isn't quite running with the leaders as far as chart performance, though it's outpacing the broader market. As of Tuesday, Comms is up 5% year to date, with the S&P 500 Index (SPX) trailing behind, roughly flat on the year.Against this backdrop, shares of GOOGL muscled ahead of their own sector (and the broader market as well), up 10% year to date (see chart below). View more earnings on GOOGLFIGURE 1: OUTPERFORMING SECTOR AND BROADER MARKET. Shares of Alphabet (GOOGL--candlestick) have outpaced the S&P 500 Index (SPX--blue line) and Communications sector ($IXC--purple line). Data sources: Nasdaq, S&P Dow Jones Indices. Chart source: The thinkorswim® platform from TD Ameritrade. For illustrative purposes only. Past performance does not guarantee future results. Heading into Q2, and similar to last quarter, Portat provided no clear guidance in terms of revenue or earnings, except that Q2 may be "a difficult one" for their advertising business.Analysts at CFRA forecast a three-year compound annual growth rate of 16% with core search, YouTube ad revenue, and Google Cloud as the company's main drivers. CFRA sees COVID-19's impact on advertising to be GOOGL's largest risk but also sees that risk being potentially offset by higher engagement in home-bound cloud services in addition to ad trends shifting from traditional media to online ad spending. As work and entertainment trends shift toward home-based services, both Pitchai and Porat seem to remain optimistic on long-term prospects. As Pitchai told analysts, "Ultimately, we'll see a long-term acceleration of movement from businesses to digital services, including increased online work, education, medicine, shopping, and entertainment. These changes will be significant and lasting."One last thing: GOOGL's plan to buy back $8.5 billion of its shares went ahead as planned, as Porat suggested it would. As you might guess, this can lend a sizable boost to EPS.GOOGL Earnings and Options Activity GOOGL is expected to report adjusted EPS of $8.23, down from $14.21 in the prior-year quarter, according to third-party consensus analyst estimates. Revenue is projected at $37.4 billion, down 4.1% from a year ago.Options traders have priced in a 4.2% share price move in either direction around the coming earnings release, according to the Market Maker Move™ indicator on the thinkorswim® platform. Looking at the July 31 options expiration, volume has been light overall, but puts have seen some activity at the 1400 and 1500 strikes. Calls have been active at the 1600 and 1800 strikes. The implied volatility sits at the 34th percentile as of Tuesday morning. Note: Call options represent the right, but not the obligation, to buy the underlying security at a predetermined price over a set period of time. Put options represent the right, but not the obligation, to sell the underlying security at a predetermined price over a set period of time.TD Ameritrade® commentary for educational purposes only. Member SIPC. Options involve risks and are not suitable for all investors. Please read Characteristics and Risks of Standardized Options.Image by Hebi B. from PixabaySee more from Benzinga * Wait For It: Tech Testimony, Fed Meeting Both On Tap, With Facebook to Follow * Late-Stage Vaccine Trials From Pfizer, Moderna May Have Encouraged Investors * How Did The Pandemic Impact Amazon's Retail And Cloud Services?(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.




from Yahoo Finance https://ift.tt/313ky0h

Here’s Why Your Federal Unemployment Benefits Could Be Delayed For Months - Forbes

Here’s Why Your Federal Unemployment Benefits Could Be Delayed For Months  Forbes

from Top stories - Google News https://ift.tt/3i0U7zd

Florida reports record increase in COVID-19 deaths for second day running - AOL

Another stimulus check could be coming—and 26 million more people might qualify for cash this time - CNBC

Judge blocks administration from implementing 'public charge' rule for immigrants during pandemic - CNN

Coronavirus live news: Brazil sees record daily cases as Hong Kong on brink of 'large-scale outbreak' - The Guardian

Anthony Davis' status to play vs. the Clippers remains 'unclear' - Woj | SportsCenter - ESPN

Apple, Amazon, Facebook, Google face claims of 'harmful' power

The executives of the four US tech giants defend their records at a five-hour hearing in Congress.

from BBC News - Technology https://ift.tt/3gbQQMR

Young people 'feel anxiety and terror' using fitness apps

A study of young people finds a fine line between getting results and becoming "obsessed".

from BBC News - Technology https://ift.tt/2Dcw5Sx

US Navy's First Black Female Fighter Pilot Will Receive Her Wings

The U.S. Navy's first Black female tactical fighter pilot, will receive her Wings of Gold on Friday.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/336d7b3

7 Best Blue Light Glasses to Reduce Eye Strain

In the market for blue light blocking glasses? A stylish pair is just a few clicks away.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/3jvYrYO

Where to Buy the Best Face Masks For Exercising

Companies like Adidas, Reebok and Onzie have started producing effective yet breathable face masks for exercising.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/3hP8Cpo

George Floyd Hologram Lights Up Over Robert E. Lee Statue in Virginia

A hologram showing George Floyd was projected in front of a Robert E. Lee statue in Richmond, Virginia on Tuesday night.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/3fdXFfv

Where to Buy The Best Face Masks That Are Stylish

Now that face masks are mandatory in many states, it's time to stock up so you can protect others from the coronavirus, in style.

[[ This is a content summary only. Visit my website for full links, other content, and more! ]]

from News https://ift.tt/30xD7ct

Tuesday, July 28, 2020

Coronavirus: Business rescue package has 'delayed the inevitable'

Insolvencies slow during lockdown, but experts say the worst is yet to come.

from BBC News - Business https://ift.tt/3jRQ3Tg

Red Sox hope bullpen steps up vs. Mets

The Boston Red Sox will host the New York Mets Monday night as both teams try to recover from dropping two of three in their respective opening series. Boston got a mild surprise when the Baltimore Orioles rebounded from a 13-2 loss on Opening Day on Friday to win the next two. The Orioles jumped out to big early leads in both weekend games and, after the pitching staff battled some control issues on Friday, they walked none in the final two games.



from Boston Red Sox News, Scores, Standings, Rumors, Videos & Highlights https://ift.tt/30PuzOn

Coronavirus: Scaled back Hajj pilgrimage due to start in Saudi Arabia

Only a very limited number of Muslims living in the kingdom will be able to make the Hajj this year.

from BBC News - World https://ift.tt/3f7LHEi

Coronavirus: Hong Kong implements strict measures amid new cases

Dining in restaurants will be banned and only two people from different households can meet.

from BBC News - World https://ift.tt/332fFH9

Spain quarantine rules: The businesses fearing for their futures

Spain's struggling tourist businesses say the UK's new quarantine rules may drive them off the edge.

from BBC News - World https://ift.tt/2Dgw000

MindMed Completes Dosing 18-MC Phase 1 Study

MindMed Completes Dosing 18-MC Phase 1 StudyNEW YORK, July 28, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC.




from Yahoo Finance https://ift.tt/3g8zXTe

Mackenzie Scott donates $1.7 billion of her wealth since split with Jeff Bezos

MindMed Completes Dosing 18-MC Phase 1 Study

MindMed Completes Dosing 18-MC Phase 1 StudyNEW YORK, July 28, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC.




from Yahoo Finance https://ift.tt/3g8zXTe

Mackenzie Scott donates $1.7 billion of her wealth since split with Jeff Bezos

Georgia governor withdraws request for emergency hearing to block Atlanta mask order | TheHill - The Hill

Americans warned not to plant mysterious seeds appearing in the mail - The Guardian

Portland protest groups sue U.S. over tear gas, rubber bullets - POLITICO

Europe faces down a second coronavirus pandemic wave - NBC News

Kodak soars another 50% after Trump announces deal to manufacture generic drug ingredients - CNBC